Intellia Therapeutics, Inc. (NASDAQ:NTLA) Posts Earnings Results

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.03, reports. The firm had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $5.83 million. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. Intellia Therapeutics’s revenue for the quarter was up 40.5% compared to the same quarter last year.

Shares of Intellia Therapeutics (NASDAQ NTLA) traded down 4.35% during trading on Friday, hitting $15.16. 334,538 shares of the company were exchanged. The company’s 50-day moving average price is $16.46 and its 200 day moving average price is $14.44. The stock’s market cap is $547.46 million. Intellia Therapeutics has a 12 month low of $10.83 and a 12 month high of $24.90.

A number of brokerages have issued reports on NTLA. Cann reissued a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, August 1st. Oppenheimer Holdings, Inc. began coverage on Intellia Therapeutics in a research report on Tuesday, July 18th. They set a “market perform” rating on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of Intellia Therapeutics in a research report on Saturday, July 22nd. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective (up previously from $19.00) on shares of Intellia Therapeutics in a research report on Wednesday, August 2nd. Finally, TheStreet raised Intellia Therapeutics from a “d+” rating to a “c-” rating in a research report on Thursday, July 6th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $24.83.

In other Intellia Therapeutics news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the business’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $16.24, for a total transaction of $2,436,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 12.80% of the company’s stock.

An institutional investor recently raised its position in Intellia Therapeutics stock. State Street Corp boosted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 52.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 164,798 shares of the company’s stock after buying an additional 56,363 shares during the period. State Street Corp owned about 0.46% of Intellia Therapeutics worth $2,638,000 as of its most recent filing with the SEC. 47.20% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by BNB Daily and is the property of of BNB Daily. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Earnings History for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply